A new proposal calls for federal investment to study how early microbial disruptions contribute to conditions like asthma, obesity, and allergies.
RT’s Three Key Takeaways:
- Chronic Disease Connections: Researchers are urging federal health agencies to fund controlled clinical trials investigating how disruptions to the human microbiome contribute to the rise of chronic conditions, including asthma, obesity, and food allergies.
- Early Development Focus: The proposal emphasizes the first 1,000 days of life, from pregnancy through age 2, as a critical window where early antibiotic exposure and cesarean delivery alter microbial development.
- Actionable Roadmap: The published plan outlines 10 priorities across four strategic areas, including advancing clinical applications, standardizing research methods globally, and integrating microbiome science into medical training.
An international group of scientists, including researchers from Rutgers University, is calling for a coordinated national research initiative to determine how microbial communities influence chronic disease development and how they can be used in clinical treatments, according to a commentary published in Nature Medicine.
The proposal comes after the US Department of Health and Human Services invited 12 leading global scientists to a roundtable discussion designed to create a framework for research and public education. While the federal agency has not yet committed additional funding, the recommendations align with priorities voiced by agency leadership to pursue focused microbiome initiatives, according to the Rutgers news release.
Early Microbial Disruption and Chronic Illness
The trillions of microorganisms that live on and inside the human body shape immune and metabolic development. Factors such as antibiotic use, cesarean delivery, infant formula, and diets containing heavily processed foods can alter these communities, according to the authors. For respiratory and primary care clinicians, these microbial shifts are of increasing interest because evidence suggests that early-life microbial disruptions correlate with the development of chronic conditions, including pediatric asthma, allergies, and metabolic disorders.
However, establishing definitive cause-and-effect relationships rather than simple correlation will require funding for large-scale, long-term controlled human trials, the authors reported.
“We hope to move quickly, with detailed proposals for particular studies and programs in this next fiscal year,” said Martin Blaser, lead author and director of the Center for Advanced Biotechnology and Medicine at Rutgers, in a news release.
The Critical First 1,000 Days
The authors highlighted the first 1,000 days of life, spanning from pregnancy through a child’s second birthday, as a vital period for intervention. They proposed longitudinal studies tracking individuals from pregnancy through adolescence to evaluate whether specific microbial disruptions directly cause long-term conditions and to evaluate potential preventive interventions.
“The microbiome develops during this period, creating an opportunity to investigate whether protecting the initial development can improve health years later,” said Maria Gloria Dominguez-Bello, henry rutgers professor of microbiome and health in the School of Environmental and Biological Sciences’ Department of Biochemistry and Microbiology, in a news release.
Four Key Strategic Areas
The authors organized their 10 research priorities into four overarching categories:
- Building scientific foundations
- Advancing clinical applications
- Pursuing high-impact opportunities
- Providing education
To date, clinical applications of microbiome science include two treatments approved by the FDA—Rebyota and Vowst—which use donor-derived stool microbes to prevent recurrent Clostridioides difficile infections following antibiotic therapy.
Beyond gastrointestinal infections, researchers are investigating how gut microbes affect immunotherapy response in cancer, as well as gut-brain connections in neurodegenerative disorders such as Parkinson’s and Alzheimer’s diseases.
The researchers also urged regulatory agencies to modernize approval standards for microbiome-based therapeutics without compromising safety, and they recommended evaluating how medications, food additives, and environmental pollutants affect microbial communities. In addition, the group advocated integrating microbiome science into standard medical curricula and public healthcare education.
“Altogether, I see this agenda as short-term as well as medium and long-term,” said Dominguez-Bello, henry rutgers professor of microbiome and health in the School of Environmental and Biological Sciences’ Department of Biochemistry and Microbiology.
